Category: Bruton Tyrosine Kinase (BTK) inhibitor

  • Novel drug to tackle inflammatory diseases begins trial

    An early-stage drug that is being developed to tackle inflammatory and autoimmune diseases has been approved by the US regulator. Inmagene Pharma’s investigational new drug (IND) application for the drug candidate IMG-004, a non-covalent, reversible, third-generation Bruton Tyrosine Kinase (BTK) inhibitor, can now proceed to a phase 1 clinical trial, following the green light from […]